Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.24 USD
+0.39 (0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $44.23 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Earnings News For RARE
-
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
-
Ultragenyx: Q4 Earnings Snapshot
-
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
-
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
-
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
-
Ultragenyx: Q3 Earnings Snapshot
-
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
-
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know
-
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
-
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
-
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
-
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
-
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
-
Ultragenyx: Q1 Earnings Snapshot
-
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
-
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
-
Ultragenyx: Q4 Earnings Snapshot
-
Ultragenyx: Q4 Earnings Snapshot
-
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
-
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
-
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
-
Ultragenyx (RARE) Down 0.9% Since Last Earnings Report: Can It Rebound?